Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in Rats
- 1 December 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 7 (6) , 575-584
- https://doi.org/10.1089/oli.1.1997.7.575
Abstract
The aim of the present study is to evaluate the in vivo toxicologic effects of a phosphorothioate oligodeoxynucleotide (PS oligo) and three of its analogs [PS oligo containing four methylphosphonate linkages at the 3‵ and 5‵-ends (MBO 1), PS oligo containing four 2‵-O-methylribonucleosides at both the 3‵- and 5‵-ends (MBO 2), and PS oligo containing an 8 bp loop region at the 3‵-end (self-stabilized oligo)]. Oligodeoxynucleotides were administrated intravenously to male and female rats at doses of 3, 10, and 30 mg/kg/day for 14 days. Rats were killed on day 15, blood samples were collected for hematology and clinical chemistry determinations, and tissues, including lymph nodes, spleens, livers, and kidneys, were subjected to pathologic examinations. The toxicity profiles of the four oligodeoxynucleotides were very similar, but differed in magnitude. In terms of the severity of the abnormalities caused by the oligodeoxynucleotides, the order was MBO 2 > PS oligo > self-stabilized oligo > MBO 1. Alterations in hematology parameters included thrombocytopenia, anemia, and neutropenia. Abnormalities in clinical chemistry parameters observed with PS oligo or MBO 2 were dose-dependent elevation of liver transaminases and reduction of the levels of alkaline phosphatase, albumin, and total protein. In addition, MBO 2 caused elevation of the total bilirubin level in male rats at the 30 mg/kg dose. No major alterations in hematology or clinical chemistry were observed in rats receiving MBO 1 or self-stabilized oligo. Dose-dependent enlargements of spleen, liver, and kidney were observed, especially in rats receiving PS oligo and MBO 2. Pathologic studies showed a generalized hyperplasia of the reticuloendothelial (RE) system in the tissues examined. Alterations in the spleen were mainly RE cell hyperplasia and hematopoietic cell proliferation. In addition to RE cell hyperplasia, lymph nodes showed necrosis, hepatocytes showed cytologic alterations and necrosis, and kidneys showed renal tubule regeneration. The severity of pathologic changes observed was oligodeoxynucleotide dependent, in the order of MBO 2 > PS oligo > self-stabilized oligo > MBO 1.Keywords
This publication has 32 references indexed in Scilit:
- Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in MiceAntisense and Nucleic Acid Drug Development, 1997
- In VivoMetabolic Profile of a Phosphorothioate OligodeoxyribonucleotideAntisense and Nucleic Acid Drug Development, 1997
- The Multiple Inhibitory Mechanisms of GEM 91®, agagAntisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1997
- In vivo studies with antisense oligonucleotidesTrends in Pharmacological Sciences, 1997
- Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley ratsToxicology, 1997
- Immune Activation by Bacterial DNA: A New Genetic CodeImmunity, 1996
- Antisense oligonucleotides: towards clinical trialsTrends in Biotechnology, 1996
- In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in ratsBiochemical Pharmacology, 1995
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotidesBioorganic & Medicinal Chemistry Letters, 1994